阅读说明：本技术 适合于il23拮抗剂疗法的患者群体 (Patient population suitable for IL23 antagonist therapy ) 是由 Q·周 于 2020-03-26 设计创作，主要内容包括：本公开提供了用于通过测量白细胞介素-22结合蛋白的血清水平和/或干扰素-γ的血清水平而选择患有适合于用抗白细胞介素-23疗法治疗的炎症性病症(比如炎症性肠病)的患者亚群或受试者的方法。另外,所述方法可用于鉴定患有适合于用抗IL-23疗法和/或抗IFN-γ疗法治疗的炎症性障碍(比如银屑病、银屑病关节炎、类风湿性关节炎、强直性脊柱炎)的患者亚群。(The present disclosure provides methods for selecting a subpopulation of patients or subjects having an inflammatory disorder (such as inflammatory bowel disease) suitable for treatment with an anti-interleukin-23 therapy by measuring serum levels of interleukin-22 binding protein and/or serum levels of interferon-gamma. In addition, the methods can be used to identify a subpopulation of patients having an inflammatory disorder (such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis) suitable for treatment with an anti-IL-23 therapy and/or an anti-IFN- γ therapy.)